進行前に検出可能な ESR1m を有する HR+/HER2-MBC における AZD9833+ CDK4/6 阻害剤を評価するための第 III 相試験 (SERENA-6) (SERENA-6)
HR+/における AZD9833 (次世代、経口 SERD) + CDK4/6 阻害剤 (パルボシクリブまたはアベマシクリブ) と継続的なアロマターゼ阻害剤 (レトロゾールまたはアナストロゾール) + CDK4/6 阻害剤への切り替えを評価するための第 III 相、二重盲検、無作為化試験アロマターゼ阻害剤 + CDK4/6 阻害剤による 1L 治療中に疾患の進行を伴わない検出可能な ESR1 変異を有する HER2-MBC 患者 - ctDNA ガイドによる早期切り替え研究
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.
調査の概要
状態
詳細な説明
Breast cancer is the most common type of cancer among women. In people with breast cancer, the body is not able to control the growth of some cells. These extra cells can form tumors in the breast. When tumor cells move to different parts of the body this is called advanced cancer. Researchers are looking for better ways to treat advanced breast cancer.
This trial will look at six drugs: palbociclib, abemaciclib, ribociclib, letrozole, anastrozole, and AZD9833. AZD9833 is the trial drug, and is the only drug not yet approved for use. Palbociclib, abemaciclib and ribociclib work in the same way and are a type of cancer drug called a CDK4/6 inhibitor. Letrozole and anastrozole work in the same way and are both a type of cancer drug called an aromatase inhibitor (AI). CDK4/6 inhibitors and AIs work together to block the tumor's ability to grow. These drugs have been approved for combined use in people with advanced breast cancer that is HR-positive and HER2-negative. But if people get mutations in the ESR1 gene, it can make the AI and CDK4/6 inhibitor treatment work less well.
The trial drug, AZD9833, is designed to work with a CDK4/6 inhibitor in the same way that an AI does. Researchers think that AZD9833 might work better with a CDK4/6 inhibitor than an AI does in people who get mutations in their ESR1 gene.
Participants in this trial will have already been receiving one of the following combinations of a CDK4/6 inhibitor and an AI:
- palbociclib + anastrozole
- palbociclib + letrozole
- abemaciclib + anastrozole
- abemaciclib + letrozole
- ribociclib + anastrozole
- ribociclib + letrozole
During the trial, participants will remain on the same CDK4/6 inhibitor that they were taking before the trial.
In this trial, the researchers want to find out how well switching a participant with an ESR1 gene mutation from an AI (letrozole or anastrozole) to AZD9833 works in the treatment of advanced breast cancer that is HR-positive and HER2-negative.
The researchers will look at which trial treatment helps the participants live longer with the cancer before it gets worse.
The researchers also want to know more about how safe AZD9833 is.
The trial participants will be split into 2 groups:
- Participants in Group A will receive AZD9833, a CDK4/6 inhibitor, and a placebo
- Participants in Group B will receive an AI, a CDK4/6 inhibitor, and a placebo
A placebo looks like a treatment but does not have any medicine in it.
A computer program will be used to randomly choose the treatments each participant gets. This helps make sure the groups are chosen fairly. Researchers do this so that comparing the results of each treatment will be as accurate as possible.
The participants will take their trial treatments over 28-day cycles, with a placebo and either AZD9833 or an AI taken once daily by mouth for all 28 days. If the participant is taking abemaciclib, they will take it twice daily by mouth for all 28 days. If the participant is taking palbociclib or ribociclib, they will take it once daily by mouth for 21 days and then stop taking it for the final 7 days of the cycle. The participant will then repeat the 28-day cycle receiving the trial treatment in the same way for as long as they are in the trial.
Participants will visit their trial site regularly throughout the trial. At these visits, the trial doctors will check the health of the participants. They will also take blood samples and do scans of the participants' tumors.
Participants will take their trial treatment until their cancer gets worse or they decide to leave the trial.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85054
- Research Site
-
-
Arkansas
-
Hot Springs、Arkansas、アメリカ、71913
- Research Site
-
Little Rock、Arkansas、アメリカ、72205
- Research Site
-
-
California
-
Long Beach、California、アメリカ、90806
- Research Site
-
San Diego、California、アメリカ、92123
- Research Site
-
Santa Rosa、California、アメリカ、92805
- Research Site
-
-
Colorado
-
Grand Junction、Colorado、アメリカ、81501
- Research Site
-
Lone Tree、Colorado、アメリカ、80124
- Research Site
-
-
Florida
-
Fort Myers、Florida、アメリカ、33901
- Research Site
-
Jacksonville、Florida、アメリカ、32256
- Research Site
-
Jacksonville、Florida、アメリカ、32224
- Research Site
-
St. Petersburg、Florida、アメリカ、33705
- Research Site
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30318
- Research Site
-
Atlanta、Georgia、アメリカ、30322
- Research Site
-
Atlanta、Georgia、アメリカ、30342
- Research Site
-
-
Illinois
-
Park Ridge、Illinois、アメリカ、60068
- Research Site
-
-
Indiana
-
Fort Wayne、Indiana、アメリカ、46804
- Research Site
-
Indianapolis、Indiana、アメリカ、46250
- Research Site
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21202
- Research Site
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- Research Site
-
Fairhaven、Massachusetts、アメリカ、02719
- Research Site
-
Foxborough、Massachusetts、アメリカ、02035
- Research Site
-
Milford、Massachusetts、アメリカ、01757
- Research Site
-
South Weymouth、Massachusetts、アメリカ、02190
- Research Site
-
-
Michigan
-
Detroit、Michigan、アメリカ、48202
- Research Site
-
Grand Rapids、Michigan、アメリカ、49503
- Research Site
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Research Site
-
-
Mississippi
-
Oxford、Mississippi、アメリカ、38655
- Research Site
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64111
- Research Site
-
St Louis、Missouri、アメリカ、63110
- Research Site
-
-
Montana
-
Billings、Montana、アメリカ、59101
- Research Site
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68130
- Research Site
-
-
New Jersey
-
Camden、New Jersey、アメリカ、08103
- Research Site
-
Ridgewood、New Jersey、アメリカ、07450
- Research Site
-
-
New York
-
Brooklyn、New York、アメリカ、11215
- Research Site
-
East Syracuse、New York、アメリカ、13057
- Research Site
-
New Hyde Park、New York、アメリカ、11042
- Research Site
-
New York、New York、アメリカ、10065
- Research Site
-
New York、New York、アメリカ、11355
- Research Site
-
Shirley、New York、アメリカ、11967
- Research Site
-
-
North Carolina
-
Goldsboro、North Carolina、アメリカ、27534
- Research Site
-
-
Ohio
-
Canton、Ohio、アメリカ、44710
- Research Site
-
Cincinnati、Ohio、アメリカ、45220
- Research Site
-
Columbus、Ohio、アメリカ、43219
- Research Site
-
-
Oregon
-
Portland、Oregon、アメリカ、97213
- Research Site
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- Research Site
-
Pittsburgh、Pennsylvania、アメリカ、15213
- Research Site
-
York、Pennsylvania、アメリカ、17403
- Research Site
-
-
South Carolina
-
Greenville、South Carolina、アメリカ、29607
- Research Site
-
West Columbia、South Carolina、アメリカ、29169
- Research Site
-
-
Tennessee
-
Knoxville、Tennessee、アメリカ、37916
- Research Site
-
Memphis、Tennessee、アメリカ、38120
- Research Site
-
Nashville、Tennessee、アメリカ、37203
- Research Site
-
-
Texas
-
Bedford、Texas、アメリカ、76022
- Research Site
-
Dallas、Texas、アメリカ、75246
- Research Site
-
Houston、Texas、アメリカ、77030
- Research Site
-
Houston、Texas、アメリカ、77024
- Research Site
-
Longview、Texas、アメリカ、75601
- Research Site
-
San Antonio、Texas、アメリカ、78240
- Research Site
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84106
- Research Site
-
-
Virginia
-
Midlothian、Virginia、アメリカ、23114
- Research Site
-
Norfolk、Virginia、アメリカ、23502
- Research Site
-
-
Washington
-
Tacoma、Washington、アメリカ、98405
- Research Site
-
-
Wisconsin
-
Waukesha、Wisconsin、アメリカ、53226
- Research Site
-
-
-
-
-
Blackpool、イギリス、FY3 8NR
- Research Site
-
Cambridge、イギリス、CB2 0QQ
- Research Site
-
London、イギリス、SW3 6JJ
- Research Site
-
London、イギリス、WC1N 3BG
- Research Site
-
Manchester、イギリス、M20 4BX
- Research Site
-
Newport、イギリス、NP10 8FZ
- Research Site
-
Nottingham、イギリス、NG5 1PB
- Research Site
-
Portsmouth、イギリス、PO6 3LY
- Research Site
-
Reading、イギリス、RG2 9LH
- Research Site
-
Sheffield、イギリス、S10 2SJ
- Research Site
-
Sutton、イギリス、SM2 5PT
- Research Site
-
Taunton、イギリス、TA1 5DA
- Research Site
-
-
-
-
-
Beersheba、イスラエル、8410101
- Research Site
-
Haifa、イスラエル、3109601
- Research Site
-
Jerusalem、イスラエル、91120
- Research Site
-
Petah Tikva、イスラエル、494142
- Research Site
-
Ramat Gan、イスラエル、5262000
- Research Site
-
-
-
-
-
Bergamo、イタリア、24127
- Research Site
-
Bologna、イタリア、40138
- Research Site
-
Florence、イタリア、50134
- Research Site
-
Meldola、イタリア、47014
- Research Site
-
Milan、イタリア、20141
- Research Site
-
Milan、イタリア、20132
- Research Site
-
Misterbianco、イタリア、95045
- Research Site
-
Naples、イタリア、80131
- Research Site
-
Padova、イタリア、35128
- Research Site
-
Roma、イタリア、00168
- Research Site
-
Rozzano、イタリア、20089
- Research Site
-
-
-
-
-
Birtinya、オーストラリア、4575
- Research Site
-
Darlinghurst、オーストラリア、2010
- Research Site
-
-
-
-
-
Graz、オーストリア、8036
- Research Site
-
Innsbruck、オーストリア、6020
- Research Site
-
Salzburg、オーストリア、5020
- Research Site
-
Vienna、オーストリア、1130
- Research Site
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2N 5G2
- Research Site
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z 4E6
- Research Site
-
-
Ontario
-
Ottawa、Ontario、カナダ、K1H 8L6
- Research Site
-
-
Quebec
-
Lévis、Quebec、カナダ、G6V 3Z1
- Research Site
-
Montreal、Quebec、カナダ、H2X 0C1
- Research Site
-
Montreal、Quebec、カナダ、H3T 1E2
- Research Site
-
Montreal、Quebec、カナダ、H1T 2M4
- Research Site
-
Québec、Quebec、カナダ、G1S 4L8
- Research Site
-
-
-
-
-
Bern、スイス、CH-3010
- Research Site
-
Chur、スイス、CH-7000
- Research Site
-
Winterthur、スイス、8401
- Research Site
-
-
-
-
-
A Coruña、スペイン、15009
- Research Site
-
Badalona、スペイン、08003
- Research Site
-
Barcelona、スペイン、8035
- Research Site
-
L'Hospitalet de Llobregat、スペイン、08908
- Research Site
-
Madrid、スペイン、28041
- Research Site
-
Madrid、スペイン、28040
- Research Site
-
Murcia、スペイン、30008
- Research Site
-
Málaga、スペイン、29010
- Research Site
-
Sant Joan Despí、スペイン、08970
- Research Site
-
Seville、スペイン、41013
- Research Site
-
Valencia、スペイン、46010
- Research Site
-
-
-
-
-
Banská Bystrica、スロバキア、974 01
- Research Site
-
Bratislava、スロバキア、833 01
- Research Site
-
Košice、スロバキア、041 91
- Research Site
-
Michalovce、スロバキア、07101
- Research Site
-
Partizánske、スロバキア、958 01
- Research Site
-
-
-
-
-
Adana、トルコ(Türkiye)、01120
- Research Site
-
Ankara、トルコ(Türkiye)、06100
- Research Site
-
Ankara、トルコ(Türkiye)、06520
- Research Site
-
Ankara、トルコ(Türkiye)、06010
- Research Site
-
Ankara、トルコ(Türkiye)、06340
- Research Site
-
Cordaleo、トルコ(Türkiye)、35575
- Research Site
-
Izmir、トルコ(Türkiye)、35100
- Research Site
-
Izmir、トルコ(Türkiye)、35360
- Research Site
-
Kadıkoy/Istanbul、トルコ(Türkiye)、34722
- Research Site
-
Kayseri、トルコ(Türkiye)、38039
- Research Site
-
-
-
-
-
Ansbach、ドイツ、91522
- Research Site
-
Augsburg、ドイツ、86156
- Research Site
-
Bonn、ドイツ、53111
- Research Site
-
Chemnitz、ドイツ、09116
- Research Site
-
Dresden、ドイツ、01307
- Research Site
-
Erlangen、ドイツ、91054
- Research Site
-
Essen、ドイツ、45130
- Research Site
-
Freiburg im Breisgau、ドイツ、79110
- Research Site
-
Hösbach、ドイツ、63768
- Research Site
-
Immenstadt im Allgäu、ドイツ、87509
- Research Site
-
Koblenz、ドイツ、56068
- Research Site
-
Leipzig、ドイツ、4103
- Research Site
-
Mannheim、ドイツ、68167
- Research Site
-
München、ドイツ、80634
- Research Site
-
Paderborn、ドイツ、33098
- Research Site
-
Ratingen、ドイツ、40878
- Research Site
-
Ravensburg、ドイツ、88212
- Research Site
-
Regensburg、ドイツ、93053
- Research Site
-
Stade、ドイツ、21680
- Research Site
-
Tübingen、ドイツ、72076
- Research Site
-
Ulm、ドイツ、89075
- Research Site
-
-
-
-
-
Drammen、ノルウェー、3004
- Research Site
-
Oslo、ノルウェー、0450
- Research Site
-
-
-
-
-
Budapest、ハンガリー、1122
- Research Site
-
Budapest、ハンガリー、1062
- Research Site
-
Miskolc、ハンガリー、3526
- Research Site
-
Szekszárd、ハンガリー、7100
- Research Site
-
Szolnok、ハンガリー、5000
- Research Site
-
Zalaegerszeg、ハンガリー、8900
- Research Site
-
-
-
-
-
Avignon、フランス、84918
- Research Site
-
Brest、フランス、29200
- Research Site
-
Clermont-Ferrand、フランス、63050
- Research Site
-
Dijon、フランス、21079
- Research Site
-
Limoges、フランス、83000
- Research Site
-
Lorient、フランス、56322
- Research Site
-
Lyon、フランス、69373
- Research Site
-
Marseille、フランス、13273
- Research Site
-
Metz-Tessy、フランス、74370
- Research Site
-
Nîmes、フランス、30029
- Research Site
-
Paris、フランス、75248
- Research Site
-
Rouen、フランス、76021
- Research Site
-
Saint-Cloud、フランス、92210
- Research Site
-
Saint-Herblain、フランス、44805
- Research Site
-
Toulouse、フランス、31100
- Research Site
-
Tours、フランス、37000
- Research Site
-
Vandœuvre-lès-Nancy、フランス、54519
- Research Site
-
Vantoux、フランス、57070
- Research Site
-
Villejuif、フランス、94805
- Research Site
-
-
-
-
-
Haskovo、ブルガリア、6300
- Research Site
-
Panagyurishte、ブルガリア、4500
- Research Site
-
Pleven、ブルガリア、5804
- Research Site
-
Plovdiv、ブルガリア、4004
- Research Site
-
Sofia、ブルガリア、1431
- Research Site
-
Sofia、ブルガリア、1407
- Research Site
-
Sofia、ブルガリア、1527
- Research Site
-
Sofia、ブルガリア、1330
- Research Site
-
Sofia、ブルガリア、1303
- Research Site
-
-
-
-
-
Leuven、ベルギー、3000
- Research Site
-
Liège、ベルギー、4000
- Research Site
-
Namur、ベルギー、5000
- Research Site
-
-
-
-
-
Guimarães、ポルトガル、4835-044
- Research Site
-
Lisbon、ポルトガル、1649-035
- Research Site
-
Lisbon、ポルトガル、1400-038
- Research Site
-
Lisbon、ポルトガル、1500-650
- Research Site
-
Lisbon、ポルトガル、1449-005
- Research Site
-
Loures、ポルトガル、2674-514
- Research Site
-
Porto、ポルトガル、4099-001
- Research Site
-
Porto、ポルトガル、4200-319
- Research Site
-
Porto、ポルトガル、4200-072
- Research Site
-
Vila Nova de Gaia、ポルトガル、4434-502
- Research Site
-
-
-
-
-
Bydgoszcz、ポーランド、85-796
- Research Site
-
Gdynia、ポーランド、81-519
- Research Site
-
Koszalin、ポーランド、75-581
- Research Site
-
Lodz、ポーランド、90-302
- Research Site
-
Poznan、ポーランド、60-693
- Research Site
-
Rzeszów、ポーランド、35-001
- Research Site
-
Tomaszów Mazowiecki、ポーランド、97-200
- Research Site
-
Warsaw、ポーランド、02-781
- Research Site
-
-
-
-
-
Moscow、ロシア、111123
- Research Site
-
Moscow、ロシア、143423
- Research Site
-
Moscow、ロシア、129090
- Research Site
-
Nizhny Novgorod、ロシア、603126
- Research Site
-
Podolsk、ロシア、142100
- Research Site
-
Saint Petersburg、ロシア、197758
- Research Site
-
Saint Petersburg、ロシア、194017
- Research Site
-
-
-
-
-
Kaohsiung City、台湾、833
- Research Site
-
Taichung、台湾、40705
- Research Site
-
Tainan、台湾、70403
- Research Site
-
Tainan、台湾、710
- Research Site
-
Taipei、台湾、100
- Research Site
-
Taipei、台湾
- Research Site
-
Taipei、台湾、11490
- Research Site
-
Taipei、台湾、23561
- Research Site
-
Taipei、台湾、11259
- Research Site
-
Taipei、台湾、110
- Research Site
-
Taoyuan、台湾、333
- Research Site
-
-
-
-
-
Chiba、日本、260-8717
- Research Site
-
Chūōku、日本、104-0045
- Research Site
-
Hidaka-shi、日本、350-1298
- Research Site
-
Hirakata-shi、日本、573-1191
- Research Site
-
Kitaadachi-gun、日本、362-0806
- Research Site
-
Kumamoto、日本、860-8556
- Research Site
-
Kōtoku、日本、135-8550
- Research Site
-
Matsuyama、日本、791-0280
- Research Site
-
Nagoya、日本、464-8681
- Research Site
-
Nagoya、日本、467-8602
- Research Site
-
Niigata、日本、951-8566
- Research Site
-
Osaka、日本、540-0006
- Research Site
-
Osaka、日本、541-8567
- Research Site
-
Ota-shi、日本、373-8550
- Research Site
-
Sapporo、日本、003-0804
- Research Site
-
Shinagawa-ku、日本、142-8666
- Research Site
-
Shinjuku-ku、日本、162-8655
- Research Site
-
Takasaki-shi、日本、370-0829
- Research Site
-
Takatsuki-shi、日本、569-8686
- Research Site
-
Tsukuba、日本、305-8577
- Research Site
-
Yokohama、日本、241-8515
- Research Site
-
-
-
-
-
Cheonan-si、韓国、31151
- Research Site
-
Daegu、韓国、42415
- Research Site
-
Goyang-si、韓国、10408
- Research Site
-
Seongnam-si、韓国、13620
- Research Site
-
Seongnam-si、韓国、463-712
- Research Site
-
Seoul、韓国、02841
- Research Site
-
Seoul、韓国、03080
- Research Site
-
Seoul、韓国、03722
- Research Site
-
Seoul、韓国、05505
- Research Site
-
Seoul、韓国、06273
- Research Site
-
Seoul、韓国、06351
- Research Site
-
Seoul、韓国、06591
- Research Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
INCLUSION CRITERIA:
INFORMATION FOR TRIAL PARTICIPANTS - Participants can join the trial if they:
- Have advanced breast cancer that is not able to be treated with surgery or radiation;
- Have an ESR1 mutation in their cancer;
- Have breast cancer that is HR-positive and HER2-negative;
- Are currently being treated with a CDK4/6 inhibitor and an AI and have been taking these drugs for at least 6 months;
- Have not had their cancer get worse after taking an AI and CDK4/6 inhibitor;
- Are able to do their daily activities;
- Are at least 18.
Full list of inclusion criteria:
- Proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent;
- Documentation of histologically confirmed diagnosis of estrogen receptor positive (ER+) /HER2- breast cancer based on local laboratory results;
- Currently on AI (letrozole or anastrozole) + CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) ± LHRH as the initial endocrine based treatment for advanced disease;
- Eastern Cooperative Oncology Group performance status of 0 or 1;
- ESR1m detected by central testing of ctDNA with Guardant360® CDx;
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;
- Adequate organ and marrow function.
EXCLUSION CRITERIA:
INFORMATION FOR TRIAL PARTICIPANTS - Participants cannot join the trial if they:
- Had certain types of tumors in the past that may come back;
- Are currently taking any other treatments for their cancer or other conditions including hormone replacements, medications, or supplements that could interfere with the trial treatment;
- Have or have had any major health problem, infection, or recent surgery that could make it difficult or dangerous to participate in this trial.
Full list of exclusion criteria:
- Advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term;
- Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease;
- Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol;
- Patient with known or family history of severe heart disease;
- Previous treatment with AZD9833, investigational SERDs or fulvestrant;
- Currently pregnant (confirmed with positive pregnancy test) or breastfeeding;
- Persistent non-haematological toxicities (CTCAE Grade > 2) caused by CDK4/6 inhibitor and/or AI treatment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:AZD9833 + palbociclib, abemaciclib or ribociclib
The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150,100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (PO, once daily) or letrozole placebo (PO, once daily) |
Dosage formulation: AZD9833 tablets will be administered orally Dosage formulation: anastrozole placebo tablets will be administrated orally. Dosage formulation: letrozole placebo tablets will be administered orally. Dosage formulation: palbociclib tablets/capsules will be administered orally Dosage formulation: abemaciclib tablets will be administered orally Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist. Dosage formulation: ribociclib tablets will be administered orally |
|
アクティブコンパレータ:Anastrozole or letrozole + palbociclib, abemaciclib or ribociclib
The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150, 100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily) |
Dosage formulation: palbociclib tablets/capsules will be administered orally Dosage formulation: abemaciclib tablets will be administered orally Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist. Dosage formulation: ribociclib tablets will be administered orally Dosage formulation: AZD9833 placebo tablets will be administrated orally. Dosage formulation: anastrozole tablets will be administered orally. Dosage formulation: letrozole tablets will be administered orally. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)
時間枠:From randomization until the earlier of the progression event or death (approximately 2 years)
|
PFS is defined as the time from randomization to objective disease progression (as assessed by RECIST 1.1) or death. |
From randomization until the earlier of the progression event or death (approximately 2 years)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free survival 2 (PFS2)
時間枠:From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)
|
PFS2 is defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death. |
From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)
|
|
Overall survival (OS)
時間枠:From randomization until the date of death due to any cause (approximately 5 years)
|
The OS is defined as the time from randomization to death due to any cause. |
From randomization until the date of death due to any cause (approximately 5 years)
|
|
Chemotherapy free survival
時間枠:From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)
|
Time to chemotherapy is defined as the time from randomization until the earlier of the start date of chemotherapy or death due to any cause. |
From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)
|
|
Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1
時間枠:From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)
|
ORR is defined as the proportion of patients who have a complete response (CR) or partial response (PR), as determined by the investigator at local site per RECIST 1.1. |
From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)
|
|
Clinical benefit rate at 24 weeks (CBR24)
時間枠:At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)
|
CBR at 24 weeks is defined as the percentage of participants who have a complete response (CR) or partial response or who have stable disease (SD) per RECIST 1.1 as assessed by the investigator at local site for At least 23 weeks after randomisation for each patient to allow for an early assessment within the assessment window (1 week window for RECIST assessment) |
At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)
|
|
Change from baseline in EORTC QLQ-C30 scale scores
時間枠:From baseline until second progression (approximately 5 years)
|
Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Scale scores range from 0-100. For functioning and global health status/ QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden. |
From baseline until second progression (approximately 5 years)
|
|
Change from baseline in EORTC QLQ-BR23 scale scores
時間枠:From baseline until second progression (approximately 5 years)
|
Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ-BR23). Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden. |
From baseline until second progression (approximately 5 years)
|
|
Plasma concentration of AZD9833 at specified timepoints
時間枠:on Day 15 for each patient
|
To assess the steady state PK of AZD9833 in combination with palbociclib or abemaciclib in all participants who receive at least one dose of AZD9833 per the protocol, for whom there are at least one reportable PK concentration. |
on Day 15 for each patient
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Fasching PA, Brufsky A, Nowecki Z, Pascual J, Moreau L, Chen SC, Karadurmus N, Gal-Yam EN, Jung KH, Pernas S, McClain S, He W, Klinowska T, Huang-Bartlett C, Turner NC; SERENA-6 Study Group. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med. 2025 Aug 7;393(6):569-580. doi: 10.1056/NEJMoa2502929. Epub 2025 Jun 1.
- Turner N, Huang-Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, Iwata H, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, McClain S, Bidard FC. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 2023 Mar;19(8):559-573. doi: 10.2217/fon-2022-1196. Epub 2023 Apr 18.
- Brufsky A, Park YH, Bidard FC, Mayer EL, Janni W, Ma C, Cristofanilli M, Bianchini G, Iwata H, Fasching PA, Nowecki Z, Pascual J, Chen SC, Moreau L, Ruiz-Borrego M, Shai A, Karadurmus N, Jung KH, Kikawa Y, Baird RD, Habash R, Sugarman R, Fox S, Selvi Miralles M, Huang Bartlett C, Turner N. SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy. Oncologist. 2026 Aug 6;31(9):oyag278. doi: 10.1093/oncolo/oyag278.
- Turner NC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Brufsky AM, Fasching PA, Nowecki Z, Pascual J, Karadurmus N, Gal-Yam E, Chung WP, Im SA, Zambelli A, Dalenc F, Oliveira M, Ishiguro H, Huang CS, Klinowska T, Fox S, Morrow C, Robert L, Huang-Bartlett C, Bidard FC. Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2026 Aug;27(8):941-958. doi: 10.1016/S1470-2045(26)00287-1. Epub 2026 Jul 13.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- 病理学的プロセス
- 腫瘍性プロセス
- 皮膚疾患
- 病理学的状態、徴候および症状
- 皮膚および結合組織疾患
- 新生物
- 乳房腫瘍
- 新生物転移
- 乳房の病気
- 部位別新生物
- ホルモン
- ホルモン、ホルモン代替品、ホルモン拮抗薬
- 下垂体ホルモン放出ホルモン
- 視床下部ホルモン
- ペプチドホルモン
- 神経ペプチド
- ペプチド
- アミノ酸、ペプチド、およびタンパク質
- オリゴペプチド
- 神経組織タンパク質
- タンパク質
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- アゾール
- ニトリル
- トリアゾール
- レトロゾール
- アナストロゾール
- ゴナドトロピン放出ホルモン
- アベマシクリブ
- ribociclib
- Palbociclib
- AZD9833
その他の研究ID番号
- D8534C00001
- 2023-503990-39-00 (その他の識別子:EU CT number)
- 2021-000546-17 (EudraCT番号)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD 共有時間枠
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共有アクセス基準
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。